Pharm/Tox Considerations for the Safety Evaluation of Nitrosamine ImpuritiesOctober 8, 2025October 8, 2025Back to: Advancing Generic Drug Development 2025 Previous LessonAddressing Potential Pitfalls in Nitrosamine Risk Assessment and ControlLesson 2 within section Session 4: Nitrosamines: Known Issues and Practical Advice. Next LessonSession 4: Q&A Panel and Day Two Closing (Advancing Generic Drug Development 2025)Lesson 4 within section Session 4: Nitrosamines: Known Issues and Practical Advice. You must enroll in this course to access course content. Presenter Xin Fu, PhD, DABTPharmacologistDPTR | OSCE | OGD | CDER | FDA Leave a Comment Cancel replyLogin with your Social IDYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment. Δ